• 9 June 2009
  • News
  • By

Bharat Biotech adopts multi-dimensional business model

Bharat Biotech adopts multi-dimensional business model
Bharat Biotech has made significant strides in manufacturing and commercializing vaccines for immunization programs worldwide.

Bharat Biotech International Ltd (BBIL) has achieved an annual turnover of Rs 234.13 crore in 2008-09 as against Rs 126 crore in 2007-08 and the company is expecting to touch Rs 300 crore in the year ahead. Bharat Biotech has evolved as a multi-dimensional biotechnology company specializing in product-oriented research, development and manufacturing of vaccines and biotherapeutics. Hyderabad-based Bharat Biotech is one of the largest manufacturers of INDIRAB (anti-rabies vaccine) in India. Bharat Biotech is a WHO prequalified manufacturer of REVAC-B (hepatitis-B vaccine) for supply to UNICEF and the only vaccine company in India to manufacture and supply a preservative (thiomersol) free vaccine, REVAC-Bmcf.
Bharat Biotech has developed a 3-dimensional business model with emphasis on biogenerics, contract manufacturing and research for developing novel products. This strategy has given Bharat Biotech the ability to earn revenues in the short and medium term while focusing on novel patent protected products that are  much needed by the developing world.
Bharat Biotech has shown significant progress in new product development and has partnered with companies from the US and Europe to co-develop, manufacture and market the products. Bharat Biotech has built productive partnerships with companies, such as Wyeth and Agennix. Bharat Biotech is one of the first companies in India to perform contract manufacturing of vaccines for global major like Wyeth, due to the IPR associated with its Hib vaccine.
Other major partnerships of Bharat Biotech are with the Department of Biotechnology, Government of India; PATH; US Centers for Disease Control and Prevention (CDC); Stanford University; US National Institutes of Health, National Institute of Allergy and Infectious Diseases (NIAID); Society for Applied Studies; National Institute of Immunology; Indo-US Vaccine Action Program; International Center for Genetic Engineering and Biotechnology (ICGEB), Thrombogenics and All India Institute of Medical Sciences.
Bharat Biotech is also now focused on developing several technology parks. According to Dr Krishna Ella, chairman and managing director of Bharat Biotech, the company’s task is to development core infrastructure and technology to enable establishment of new companies whereby new local entrepreneurs in the biotechnology field will be created. 

Leave a Reply Sign in

Notify me of follow-up comments via e-mail address

Post Comment

Survey Box

National Health Policy

Is National Health Policy 2017 helpful for patients?

Send this article by email